Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Nicorandil

Criteria

Inclusion Criteria:

• 18-80 years;

• acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;

Exclusion Criteria:

• systolic blood pressure<100mmHg;

• cardiac shock;

• aortic dissection;

• history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting (<6 month);

• history of the treatment of nicorandil (<6 month);

• history of intravenous nitrates before percutaneous coronary intervention;

• contraindicated or intolerable to nicorandil;

• pregnant or lactation period;

• patients with an estimated survival time of less than 1 year.